Palo Alto, California, June 29, 2022 (GLOBE NEWSWIRE) -- Rayont Inc. ("Rayont" or the "Company") (OTC QB: RAYT), an international healthcare company specializing in the manufacturing, distribution of alternative medicine products and services across the entire value chain, announced that on 29 of June 2022 it has signed the Asset Sale Agreement for sale of Next Generation Photo Dynamic Therapy (NGPDT) License for Sub-Sahara Africa and its equipment.
The sale as described in Asset Sale Agreement between Rayont (Australia) Pty Ltd ("Asset Seller"), Rayont International (L) Limited ("License Seller") and Nova Medical Group Pty Ltd ("Buyer") is for a consideration of USD 3,500,000 or equivalent to AUD 5,000,000 where the consideration is split as follows:
• License for Sub-Sahara Africa – USD 2,500,000
• Equipment – USD 1,000,000
The company shall file an 8K with The Securities and Exchange Commission within time required to disclose the details of the deal.
"The decision to sell NGPDT License and equipment was a difficult one given the promise the technology could offer to cancer patients. This sale following the sale of Rayont Technologies earlier this year is a clear indication of our strategic intent to focus of Complementary Alternative Medicine and profit generating assets within the segment. The cash to be generated over time from this sale improves the cash position and liquidity of Rayont Group" said Rayont's President & CEO, Ms Marshini Aliya Moodley.
About Rayont Inc.
Rayont, Inc. (RAYT) is a public traded company incorporated in Nevada, USA since its inception in 2011. In 2018, the Company repositioned itself to focus on healthcare including the manufacturing and, distribution of alternative medicine products and services across the entire value chain.
Over past few year the Company has built a portfolio of businesses focusing on natural and alternative medicine products and services, personalized healthcare for patients based on scientific reliable tests aimed to provide positive results to improve the patients` healthcare and quality of life.
For further information, please visit
SAFE HARBOR
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
Company Contact:
Investor Relations
ir@rayont.com
Palo Alto, California, June 29, 2022 (GLOBE NEWSWIRE) -- Rayont Inc. ("Rayont" or the "Company") (OTC QB: RAYT), an international healthcare company specializing in the manufacturing, distribution of alternative medicine products and services across the entire value chain, announced that on 29 of June 2022 it has signed the Asset Sale Agreement for sale of Next Generation Photo Dynamic Therapy (NGPDT) License for Sub-Sahara Africa and its equipment.
加利福尼亚州帕洛阿尔托，2022年6月29日(Global Newswire)--致力于在整个价值链上制造、分销替代医学产品和服务的国际医疗保健公司Rayont Inc.(以下简称“Rayont”或“公司”)(场外QB：RAYT)宣布，它已于2022年6月29日签署了资产出售协议，出售撒哈拉以南非洲地区及其设备的下一代光动力疗法(NGPDT)许可证。
The sale as described in Asset Sale Agreement between Rayont (Australia) Pty Ltd ("Asset Seller"), Rayont International (L) Limited ("License Seller") and Nova Medical Group Pty Ltd ("Buyer") is for a consideration of USD 3,500,000 or equivalent to AUD 5,000,000 where the consideration is split as follows:
Rayont(Australia)Pty Ltd(“资产卖方”)、Rayont International(L)Limited(“许可证卖方”)和Nova Medical Group Pty Ltd(“买方”)之间的资产出售协议中所述的出售，代价为3,500,000美元或相当于5,000,000澳元，其中代价分为以下几部分：
• License for Sub-Sahara Africa – USD 2,500,000
• Equipment – USD 1,000,000
The company shall file an 8K with The Securities and Exchange Commission within time required to disclose the details of the deal.
该公司应在披露交易细节的要求时间内向美国证券交易委员会(Securities And Exchange Commission)提交8K文件。
"The decision to sell NGPDT License and equipment was a difficult one given the promise the technology could offer to cancer patients. This sale following the sale of Rayont Technologies earlier this year is a clear indication of our strategic intent to focus of Complementary Alternative Medicine and profit generating assets within the segment. The cash to be generated over time from this sale improves the cash position and liquidity of Rayont Group" said Rayont's President & CEO, Ms Marshini Aliya Moodley.
Rayont总裁兼首席执行官Marshini Aliya Moodley女士表示：“考虑到这项技术可能为癌症患者提供的前景，出售NGPDT许可证和设备的决定是一个困难的决定。今年早些时候出售Rayont Technologies之后的这次出售清楚地表明了我们专注于补充替代医学和该部门的盈利资产的战略意图。随着时间的推移，出售所产生的现金将改善Rayont集团的现金状况和流动性。”
Rayont, Inc. (RAYT) is a public traded company incorporated in Nevada, USA since its inception in 2011. In 2018, the Company repositioned itself to focus on healthcare including the manufacturing and, distribution of alternative medicine products and services across the entire value chain.
Rayont，Inc.(RAYT)是一家上市公司，自2011年成立以来一直在美国内华达州成立。2018年，该公司重新定位，专注于医疗保健，包括在整个价值链上制造和分销替代药物产品和服务。
Over past few year the Company has built a portfolio of businesses focusing on natural and alternative medicine products and services, personalized healthcare for patients based on scientific reliable tests aimed to provide positive results to improve the patients` healthcare and quality of life.
在过去的几年里，该公司建立了一系列业务，专注于天然和替代药物产品和服务，基于科学可靠的测试为患者提供个性化医疗保健，旨在提供积极的结果，以改善患者的医疗保健和生活质量。
For further information, please visit
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
本新闻稿中的某些陈述可能包含1933年《证券法》第175条规定的前瞻性信息，受1934年《证券交易法》第3b-6条的约束，并受这些规定所创造的安全港的约束。本新闻稿中包含的除事实陈述外的所有陈述，包括但不限于有关公司潜在的未来计划和目标的陈述，均为前瞻性陈述，涉及风险和不确定性。不能保证这样的陈述将被证明是准确的，其他结果和进一步的事件可能与这种陈述中预期的大不相同。未来的事件和实际结果可能与前瞻性陈述中陈述的、预期的或潜在的大不相同。
Company Contact:
Investor Relations
ir@rayont.com
公司联系人：
投资者关系
邮箱：ir@rayont.com
